VG Life Sciences is a small, publicly traded biotechnology company specializing in immune-targeted therapy. The lead product of VG is our newly developed peptide therapy for post-infectious and chronic inflammatory diseases. The peptide was computationally designed for its high binding constant to the peptide binding groove of Major Histocompatibility Molecules (MHC gene products/immune response gene products) that are expressed on professional antigen presenting cells that promote inflammation. The peptide has been used in several animal models of chronic inflammatory diseases, including post-traumatic brain injury, Theiler's virus associated epilepsy, and mouse and rate models of sepsis. The peptide is currenly in safety, pharmacokinetics, and toxicology studies as a part of our application for FDA approval.